Inasmuch as cancer cells may not be approvable for the growth of clinical-grade oncolytic HSVs (o-HSVs) and the retargeted HSVs require the HER2 oncogene to infect cells, we reasoned that even a non-cancer cell line, transgenically expressing HER2, might not be considered approvable by the regulatory agencies. Here, ERBB2 is linked to cancer.